[144] Health Catalyst, Inc SEC Filing
Health Catalyst, Inc. (HCAT) reported a Form 144 notice showing a proposed sale of 3,360 common shares through Morgan Stanley Smith Barney on 09/02/2025 with an aggregate market value of $11,298.67. The shares were acquired the same day as restricted stock issued by Health Catalyst as compensation. The filing lists 70,373,625 shares outstanding and indicates no securities sold by the reporting person in the past three months. The filer certifies no undisclosed material adverse information and provides standard Form 144 representations.
Health Catalyst, Inc. (HCAT) ha presentato un avviso Form 144 che segnala la proposta vendita di 3.360 azioni ordinarie tramite Morgan Stanley Smith Barney in data 09/02/2025, per un valore di mercato complessivo di $11,298.67. Le azioni sono state acquisite lo stesso giorno come restricted stock emesse da Health Catalyst a titolo di compenso. La dichiarazione riporta 70.373.625 azioni in circolazione e indica che la persona segnalante non ha venduto titoli negli ultimi tre mesi. Il dichiarante certifica l'assenza di informazioni materiali sfavorevoli non divulgate e fornisce le consuete attestazioni del Form 144.
Health Catalyst, Inc. (HCAT) presentó un aviso Form 144 que indica la propuesta de venta de 3.360 acciones ordinarias a través de Morgan Stanley Smith Barney el 09/02/2025, con un valor de mercado agregado de $11,298.67. Las acciones se adquirieron el mismo día como restricted stock emitidas por Health Catalyst como compensación. La presentación señala 70,373,625 acciones en circulación e indica que la persona informante no vendió valores en los últimos tres meses. El declarante certifica que no existe información material adversa no divulgada y aporta las representaciones habituales del Form 144.
Health Catalyst, Inc. (HCAT)는 09/02/2025에 Morgan Stanley Smith Barney를 통해 보통주 3,360주를 매각할 예정임을 알리는 Form 144 통지를 제출했으며, 총 시가 가치는 $11,298.67입니다. 해당 주식은 같은 날 Health Catalyst가 보상으로 발행한 restricted stock으로 취득되었습니다. 제출서류에는 유통 주식수 70,373,625주가 기재되어 있으며 보고인은 지난 세 달 동안 증권을 매도하지 않았다고 표시되어 있습니다. 제출인은 미공개 중대한 불리한 정보가 없음을 증명하고 Form 144의 표준 진술을 제공합니다.
Health Catalyst, Inc. (HCAT) a déposé un avis Form 144 indiquant la vente proposée de 3 360 actions ordinaires via Morgan Stanley Smith Barney le 09/02/2025, pour une valeur de marché agrégée de $11,298.67. Les actions ont été acquises le même jour en tant que restricted stock émises par Health Catalyst à titre de rémunération. Le dépôt mentionne 70,373,625 actions en circulation et indique que la personne déclarante n'a pas vendu de titres au cours des trois derniers mois. Le déclarant certifie l'absence d'informations défavorables non divulguées et fournit les représentations standard du Form 144.
Health Catalyst, Inc. (HCAT) meldete eine Form-144-Mitteilung über den geplanten Verkauf von 3.360 Stammaktien über Morgan Stanley Smith Barney am 09/02/2025 mit einem Gesamtmarktwert von $11,298.67. Die Aktien wurden am selben Tag als restricted stock erworben, die Health Catalyst als Vergütung ausgegeben hatte. Die Einreichung gibt 70.373.625 ausstehende Aktien an und weist darauf hin, dass die meldende Person in den letzten drei Monaten keine Wertpapiere verkauft hat. Der Einreicher bestätigt, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen, und macht die üblichen Erklärungen des Form 144.
- None.
- None.
Insights
TL;DR Insider proposes to sell a small block of restricted shares acquired as compensation; size appears immaterial to capitalization.
The notice documents a proposed sale of 3,360 common shares valued at $11,298.67 executed via Morgan Stanley Smith Barney on 09/02/2025. These shares were acquired the same day as restricted stock issued by Health Catalyst and paid as compensation. Relative to the reported 70,373,625 shares outstanding, the block represents a negligible fraction of outstanding equity, suggesting limited market or governance impact. The filing confirms no sales in the prior three months and includes the standard attestation regarding material nonpublic information. From a compliance and disclosure perspective, the Form 144 appears routine and complete based on the provided fields.
TL;DR Routine disclosure of an insider sale tied to compensation; no red flags in the provided information.
The filing shows acquisition as restricted stock and subsequent proposed sale, a common sequence for awards subject to Rule 144 conditions. The inclusion of broker details and the attestation about material information align with regulatory expectations. Because the position size is minimal relative to total shares outstanding and there are no prior recent sales reported, this notice is unlikely to raise governance or signaling concerns based on the disclosed data alone.
Health Catalyst, Inc. (HCAT) ha presentato un avviso Form 144 che segnala la proposta vendita di 3.360 azioni ordinarie tramite Morgan Stanley Smith Barney in data 09/02/2025, per un valore di mercato complessivo di $11,298.67. Le azioni sono state acquisite lo stesso giorno come restricted stock emesse da Health Catalyst a titolo di compenso. La dichiarazione riporta 70.373.625 azioni in circolazione e indica che la persona segnalante non ha venduto titoli negli ultimi tre mesi. Il dichiarante certifica l'assenza di informazioni materiali sfavorevoli non divulgate e fornisce le consuete attestazioni del Form 144.
Health Catalyst, Inc. (HCAT) presentó un aviso Form 144 que indica la propuesta de venta de 3.360 acciones ordinarias a través de Morgan Stanley Smith Barney el 09/02/2025, con un valor de mercado agregado de $11,298.67. Las acciones se adquirieron el mismo día como restricted stock emitidas por Health Catalyst como compensación. La presentación señala 70,373,625 acciones en circulación e indica que la persona informante no vendió valores en los últimos tres meses. El declarante certifica que no existe información material adversa no divulgada y aporta las representaciones habituales del Form 144.
Health Catalyst, Inc. (HCAT)는 09/02/2025에 Morgan Stanley Smith Barney를 통해 보통주 3,360주를 매각할 예정임을 알리는 Form 144 통지를 제출했으며, 총 시가 가치는 $11,298.67입니다. 해당 주식은 같은 날 Health Catalyst가 보상으로 발행한 restricted stock으로 취득되었습니다. 제출서류에는 유통 주식수 70,373,625주가 기재되어 있으며 보고인은 지난 세 달 동안 증권을 매도하지 않았다고 표시되어 있습니다. 제출인은 미공개 중대한 불리한 정보가 없음을 증명하고 Form 144의 표준 진술을 제공합니다.
Health Catalyst, Inc. (HCAT) a déposé un avis Form 144 indiquant la vente proposée de 3 360 actions ordinaires via Morgan Stanley Smith Barney le 09/02/2025, pour une valeur de marché agrégée de $11,298.67. Les actions ont été acquises le même jour en tant que restricted stock émises par Health Catalyst à titre de rémunération. Le dépôt mentionne 70,373,625 actions en circulation et indique que la personne déclarante n'a pas vendu de titres au cours des trois derniers mois. Le déclarant certifie l'absence d'informations défavorables non divulguées et fournit les représentations standard du Form 144.
Health Catalyst, Inc. (HCAT) meldete eine Form-144-Mitteilung über den geplanten Verkauf von 3.360 Stammaktien über Morgan Stanley Smith Barney am 09/02/2025 mit einem Gesamtmarktwert von $11,298.67. Die Aktien wurden am selben Tag als restricted stock erworben, die Health Catalyst als Vergütung ausgegeben hatte. Die Einreichung gibt 70.373.625 ausstehende Aktien an und weist darauf hin, dass die meldende Person in den letzten drei Monaten keine Wertpapiere verkauft hat. Der Einreicher bestätigt, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen, und macht die üblichen Erklärungen des Form 144.
FAQ
What did Health Catalyst's Form 144 for HCAT disclose?
How were the 3,360 HCAT shares acquired?
Does the Form 144 show recent sales by the reporting person?
Who is the broker handling the proposed HCAT sale?
What portion of Health Catalyst's outstanding shares does this sale represent?
